Evidence map›Paper›PMID 33194046›Full record

ArticleAmerican journal of translational research2020

LASP1 induces colorectal cancer proliferation and invasiveness through Hippo signaling and Nanog mediated EMT.

Na Chen, Xiangdong Han, Xue Bai, Bo Yin, Yubin Wang

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Na ChenDepartment of General Surgery, The First Affiliated Hospital of Jinzhou Medical University Jinzhou, Liaoning Province, China.
Xiangdong HanDepartment of General Surgery, The First Affiliated Hospital of Jinzhou Medical University Jinzhou, Liaoning Province, China.
Xue BaiDepartment of General Surgery, The First Affiliated Hospital of Jinzhou Medical University Jinzhou, Liaoning Province, China.
Bo YinDepartment of General Surgery, The First Affiliated Hospital of Jinzhou Medical University Jinzhou, Liaoning Province, China.
Yubin WangDepartment of General Surgery, The First Affiliated Hospital of Jinzhou Medical University Jinzhou, Liaoning Province, China.
Jinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of LIM and SH3 protein 1 (LASP1) in colorectal cancer (CRC) has been described in multiple studies, however, the underlying molecular mechanisms remained inclusive. In the present study, we performed immunohistochemistry (IHC) staining for LASP1 and found that LASP1 expression was higher in CRC tissue of advanced stage. Over-expressed (OE) LASP1 promoted proliferation, tumorigenesis and migration of CRC cell lines SW480 and SW620. Using the TCGA database, we identified Yes-associated protein (YAP1) was positively correlated with LASP1 expression in CRC patients. Introducing a novel YAP1 inhibitor CA3, we found that CA3 treatment inhibited LAPS1 OE SW480 and SW620 cells proliferation, colony number formation, invasion and migration. Further mechanistic experiments showed that Nanog, a stem cell marker, was up-regulated in LASP1 OE cells but suppressed by CA3 treatment. Chromatin immunoprecipitation (CHIP) and luciferase reporter assay revealed that YAP1 can directly target the promoter region of

Indexed as

colorectal cancerHippo signaling pathwayLASP1

Identifiers

PMID33194046
PMCPMC7653627
OpenAlexW3098590004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.